natgillin/translations-raw huggingface dataset:
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Granupas opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Granupas’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Harvoni opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Harvoni’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Hemangiol opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hemangiol’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Hetlioz opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hetlioz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Hexacima opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hexacima’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Hexyon opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Iblias opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Iblias’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Iclusig opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Iclusig’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Ikervis opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ikervis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Imbruvica opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Imbruvica’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Incresync er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Incresync’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Inductos opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Inductos are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Ionsys er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ionsys’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Izba opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Izba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Jetrea opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Jetrea outweigh its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Jinarc opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Jinarc’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Kadcyla opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kadcyla’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Kanuma opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kanuma’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Kengrexal opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kengrexal’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Keytruda opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Keytruda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Kolbam opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kolbam’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Kovaltry opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Lenvima opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lenvima’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Lixiana opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lixiana’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Lonsurf opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lonsurf’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Lynparza opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lynparza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Mekinist opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Mekinist’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Mirvaso opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Mirvaso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Moventig opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Moventig’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Mysimba opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
On the balance of the available evidence the CHMP decided that Mysimba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Neparvis opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Neparvis are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Nivolumab BMS opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nivolumab BMS’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved NovoRapid opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that NovoRapid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Nucala opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nucala’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Nuedexta er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nuedexta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Numient opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Numient’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Obizur opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Obizur are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Ofev overstiger risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ofev’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Ongentys opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ongentys’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Onivyde opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Onivyde’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Opdivo opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Opdivo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Opsumit opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Opsumit’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Orkambi opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Orkambi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Otezla opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Otezla’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Plegridy opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that Plegridy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Portrazza er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Portrazza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Praluent opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Praluent’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Qtern opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Qtern’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Quinsair opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Quinsair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Raplixa opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Raplixa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Ravicti opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Ravicti are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Repatha opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Repatha’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Revatio opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Revatio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Revinty Ellipta opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Revinty Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Rezolsta opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Rezolsta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Ristempa opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ristempa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Rixubis opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Rixubis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Saxenda opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Saxenda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Scenesse opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse for Scenesse.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Scenesse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Senshio opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Senshio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Sevelamer carbonate Zentiva overstiger risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sevelamer carbonate Zentiva’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Sialanar opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that benefits of Sialanar outweigh its risks and recommended that it be granted marketing authorisation in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Sivextro opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sivextro’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Sovaldi opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sovaldi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Stayveer er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stayveer’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Stelara opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stelara’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Strensiq opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Strensiq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Stribild er større end risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stribild’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Strimvelis opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Strimvelis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Sylvant opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sylvant’s benefits are greater than its risks and recommended that it be approved for use in the EU.